NIKKEI 225
37,942.92 -517.16 (-1.34%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.72 -0.09 (-0.11%) GOLD FUTURES
2,329.60 -8.80 (-0.38%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,849.48 -1,700.02 (-3.17%)
Jazz Pharmaceuticals PLC (J7Z.SG)
- PR Newswire
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago. Presentations include data from trials of zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.
- Simply Wall St.
A Closer Look At Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Uninspiring ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- PR Newswire
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
